Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease
Generate an AI Snapshot to get a quick, structured summary of this paper.
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
A prospective longitudinal study of symptomless individuals at risk of familial Alzheimer’s disease, finding that five at-risk patients developed symptoms of cognitive decline during follow-up and subsequently progressed to fulfil established criteria for probable Alzheimer's disease.
Abstract
Quantitative cross-sectional magnetic resonance imaging (MRI) studies of Alzheimer's disease have shown that atrophy is already present even in mildly affected individuals. 1 Jack-CR J Petersen RC Yue CX et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology. 1997; 49: 786-794 Crossref PubMed Scopus (929) Google Scholar However, single measures of structures with a wide normal range are not as sensitive as repeated measures in progressive disorders such as Alzheimer's disease. Subtraction of registered serial MRI provides an accurate method of measuring small amounts of diffuse cerebralvolume change. In this way rates of atrophy have been found to be ten to 40 times greater in mild to moderate Alzheimer's disease than in normal ageing. 2 Fox NC Freeborough PA Rossor MN Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet. 1996; 348: 94-97 Summary Full Text Full Text PDF PubMed Scopus (316) Google Scholar , 3 Fox NC Freeborough PA Brain atrophy progression measured from registered serial MIR: validation and application to Alzheimer's disease. JMRI. 1997; 7: 1069-1075 Crossref Scopus (293) Google Scholar We have used this technique to assess whether rates of atrophy were increased at an even earlier stage of the disease. We did a prospective longitudinal study of symptomless individuals at risk of familial Alzheimer's disease. Individuals were defined as at risk if they had a family history of autosomal dominant early-onset (<65 years) Alzheimer's disease and were within 5 years of the age at onset in their family. Patients were regarded as symptomless if they and their close informants felt there were no symptoms of memory loss or other cognitive decline.